BMP‐ACVR1 Axis is Critical for Efficacy of PRC2 Inhibitors in B‐Cell Lymphoma

Abstract

Abstract EZH2 is the catalytic subunit of the histone methyltransferase Polycomb Repressive Complex 2 (PRC2), and its somatic activating mutations drive lymphoma, particularly the germinal center B‐cell type. Although PRC2 inhibitors, such as tazemetostat, have demonstrated anti‐lymphoma activity in patients, the clinical efficacy is not limited to EZH2‐mutant lymphoma. In this study, Activin A Receptor Type 1 (ACVR1), a type I Bone Morphogenetic Protein (BMP) receptor, is identified as critical for the anti‐lymphoma efficacy of PRC2 inhibitors through a whole‐genome CRISPR screen. BMP6, BMP7, and ACVR1 are repressed by PRC2‐mediated H3K27me3, and PRC2 inhibition upregulates their expression and signaling in cell and patient‐derived xenograft models. Through BMP‐ACVR1 signaling, PRC2 inhibitors robustly induced cell cycle arrest and B cell lineage differentiation in vivo. Remarkably, blocking ACVR1 signaling using an inhibitor or genetic depletion significantly compromised the in vitro and in vivo efficacy of PRC2 inhibitors. Furthermore, high levels of BMP6 and BMP7, along with ACVR1, are associated with longer survival in lymphoma patients, underscoring the clinical relevance of this study. Altogether, BMP‐ACVR1 exhibits anti‐lymphoma function and represents a critical PRC2‐repressed pathway contributing to the efficacy of PRC2 inhibitors.

Keywords

• ACVR1
• B‐cell lymphoma
• biomarker
• BMP
• cancer therapeutics
• PRC2 inhibitors